2011

1. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor,,in patients with advanced solid tumors

   Journal of Clinical Oncology, Vol. 29, Núm. 28, pp. 3783-3790